Pompe disease is a rare autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA), leading to pathological glycogen accumulation in skeletal, cardiac, and smooth muscle. [1-2] Estimated incidence ranges from 1 in 4,000 to 1 in 350,000 live births, with over 500 disease-causing GAA variants identified. [2] The disease exists on a clinical spectrum: infantile-onset Pompe disease (IOPD) presents with near-complete enzyme deficiency, cardiomyopathy, and death within the first year if untreated; late-onset Pompe disease (LOPD) accounts for >80% of cases and presents with progressive proximal/axial weakness and respiratory insufficiency at any age. [2-3]
1. History
- Key HPI questions: Age of symptom onset; progressive proximal weakness (difficulty climbing stairs, rising from chairs, frequent falls); exercise intolerance and fatigue; respiratory symptoms (orthopnea, morning headaches, daytime somnolence, sleep-disordered breathing) [4-5]
- Symptom characterization: Insidious onset of limb-girdle weakness, typically legs > arms; diaphragmatic weakness may be disproportionate to limb weakness; in LOPD, respiratory failure can be the presenting symptom even while still ambulatory [5]
- Timing/progression: IOPD: symptoms within first 3 months of life (hypotonia, feeding difficulties, cardiomegaly). LOPD: mean age of presentation ~28 years, but 18% present before age 12 [4]
- Associated symptoms: Myalgia, cramps, stiffness; post-exercise rhabdomyolysis with pigmenturia (LOPD); feeding/swallowing difficulties; macroglossia (IOPD) [6-7]
- Important negatives: Absence of cardiac involvement in LOPD (distinguishes from IOPD); absence of cognitive impairment; absence of sensory deficits [3-4]
2. Alarm Features
- Acute respiratory failure — diaphragmatic weakness can cause sudden decompensation, especially during respiratory infections [2][5]
- Cardiopulmonary collapse in IOPD — hypertrophic cardiomyopathy with LVOT obstruction; risk of tachyarrhythmia and sudden death, especially with stress, fever, dehydration, or anesthesia [7]
- Aspiration — swallowing dysfunction with pooling of secretions; "wet" vocal quality indicating laryngeal penetration [7]
- Anesthesia-related cardiac arrest — reported with halothane, sevoflurane, and propofol in IOPD [7]
- Rapid motor decline in infants — failure to achieve motor milestones, progressive hypotonia ("floppy baby") [3]
3. Medications
- Enzyme Replacement Therapy (ERT):
- Alglucosidase alfa (Lumizyme/Myozyme): 20 mg/kg IV every 2 weeks; approved for all Pompe disease [4][8]
- Avalglucosidase alfa (Nexviazyme): next-generation ERT with ~15-fold higher M6P content; approved for LOPD age ≥1 year [2][9]
- Cipaglucosidase alfa + miglustat (Pombiliti + Opfolda): approved for adults with LOPD ≥40 kg not improving on current ERT [2][10]
- For IOPD, many centers now use 40 mg/kg biweekly or weekly dosing, which has shown improved survival and motor outcomes [2]
- Contraindicated/caution medications:
- Digoxin, inotropes, diuretics, afterload-reducing agents (ACE inhibitors) — may worsen LVOT obstruction in early-stage IOPD cardiomyopathy [3][7]
- Beta-blockers — anecdotal reports of sudden death; use judiciously [7]
- Succinylcholine — contraindicated due to risk of rhabdomyolysis and hyperkalemia [7][11]
- Volatile anesthetic agents — risk of rhabdomyolysis; malignant hyperthermia precautions should be taken [7][11]
- Propofol — deaths reported in IOPD patients; afterload reduction risks myocardial ischemia [7]
- Safer anesthetic agents: Ketamine (maintains SVR and contractility) and etomidate are preferred [7]
- Infusion-associated reactions with ERT (~25%): managed with antihistamines, corticosteroids, or slowing infusion rate [2]
- CRIM-negative patients require immunomodulation (rituximab, methotrexate, IVIG) before initiating ERT to prevent high-titer anti-drug antibodies [2-3]
4. Diet
- High-protein, low-carbohydrate diet has been studied as adjunctive therapy in LOPD — rationale is to decrease glycogen deposition, increase fatty acid utilization, and compensate for increased amino acid oxidation [7][12]
- A 12-week intervention with 2 g/kg/day protein combined with exercise improved muscle strength, fatigue, and quality of life in children with Pompe disease [13]
- Exercise + high-protein diet (25–30% protein, 30–35% carbohydrate, 35–40% fat) in LOPD adults on ERT improved peak aerobic power, reduced CK/LDH, and improved FEV1 and quality of life [12]
- Adequate caloric intake is critical — jaw muscle fatigue and dysphagia can lead to inadequate nutrition and endogenous muscle protein breakdown [7]
- Texture modification (soft diet, pureed foods) may be necessary for those with swallowing difficulties [7]
- Vitamin D, calcium, and bisphosphonate supplementation per neuromuscular disease guidelines for osteoporosis prevention [14]
5. Review of Systems
- Musculoskeletal: Proximal weakness, difficulty with stairs/rising, frequent falls, scoliosis, contractures, myalgia [3][14]
- Respiratory: Orthopnea, morning headaches, daytime somnolence, sleep apnea, dyspnea on exertion, recurrent respiratory infections [4-5]
- Cardiac (IOPD): Cardiomegaly, palpitations, exercise intolerance [2][6]
- GI/Nutrition: Feeding difficulties, dysphagia, failure to thrive, GE reflux [7]
- Neurologic: Hypotonia, hearing loss, delayed motor milestones [2][15]
- Vascular (LOPD): Arteriopathy, ascending aortic dilatation, cerebral vasculopathy [3][6]
- Skeletal: Osteopenia/osteoporosis, scoliosis [14-15]
6. Collateral History and Family History
- Autosomal recessive inheritance — consanguinity increases risk; both parents are obligate carriers [3]
- Inquire about affected siblings, unexplained infant deaths, or family members with unexplained myopathy or respiratory failure
- All at-risk siblings should be tested regardless of age to allow early diagnosis and treatment [3]
- Social context: assess caregiver burden, access to infusion centers, home infusion capability, and palliative care needs [3]
7. Risk Factors
- Genetic: Two pathogenic GAA variants; >500 disease-causing mutations identified; most common is c.-32-13T→G (IVS1) splicing variant [2]
- CRIM-negative status (no residual GAA protein) — associated with poorer outcomes on ERT due to high-titer antibody formation [2][16]
- Diagnostic delay averages 4.1 years in LOPD, during which irreversible muscle damage progresses [17]
- Ethnicity: Incidence varies by population (higher in African American and Chinese populations for IOPD) [2]
- Comorbidities increasing risk: Respiratory infections, obesity (worsens respiratory mechanics), scoliosis (compounds restrictive lung disease) [14]
8. Differential Diagnosis
- Limb-girdle muscular dystrophies (LGMDs) — most common misdiagnosis in LOPD; overlap in proximal weakness pattern [17]
- Danon disease (LAMP2 mutation) — X-linked; HCM with WPW pattern on ECG; intellectual disability; distinguished by LAMP2 gene testing [18-19]
- PRKAG2 cardiomyopathy — glycogen storage with HCM and pre-excitation; autosomal dominant [18]
- GSD III (Cori/Forbes disease) — hepatomegaly more prominent; can present with HCM [18]
- Myasthenia gravis — fatigable weakness but no CK elevation; positive antibodies
- Polymyositis/inflammatory myopathies — elevated CK but inflammatory infiltrate on biopsy; responds to immunosuppression
- Spinal muscular atrophy — anterior horn cell disease; no cardiac involvement; genetic testing distinguishes
- Duchenne/Becker muscular dystrophy — X-linked; dystrophin deficiency; different biopsy findings
- Respiratory-onset LOPD may mimic diaphragmatic paralysis, COPD, or neuromuscular junction disorders [5]
9. Past Medical History
- Previous episodes of unexplained CK elevation, rhabdomyolysis, or pigmenturia [6]
- History of unexplained respiratory failure or need for ventilatory support
- Delayed motor milestones in childhood
- Scoliosis surgery or orthopedic interventions
- Prior anesthetic complications (cardiac arrest, prolonged recovery)
- Chronic conditions: osteoporosis, sleep apnea, cardiomyopathy
- Newborn screening status — Pompe disease was added to the US RUSP in 2015 [20]
10. Physical Exam
- Vital signs: Tachypnea, hypoxia (especially supine), tachycardia
- IOPD: Profound hypotonia ("floppy baby"), head lag, slipping through on vertical suspension, macroglossia, hepatomegaly, massive cardiomegaly, decreased tendon reflexes [2][15]
- LOPD: Proximal weakness (Gowers' sign, Trendelenburg gait), paraspinal muscle weakness, scapular winging, lumbar lordosis, scoliosis [3][14]
- Respiratory exam: Paradoxical abdominal breathing (diaphragmatic weakness), reduced breath sounds at bases, use of accessory muscles
- Focused maneuvers: Assess hip flexor, hip abductor, and neck extensor strength; evaluate for Trendelenburg sign; supine vs. upright FVC (>10% drop suggests diaphragmatic weakness) [14]
- Absent or reduced deep tendon reflexes in affected muscle groups
11. Lab Studies
- First-line screening: GAA enzyme activity on dried blood spot (DBS) — measured by tandem mass spectrometry (preferred over fluorimetry to reduce pseudodeficiency false positives) [21-22]
- Confirmatory: GAA enzyme activity in leukocytes or fibroblasts + GAA gene sequencing (essential for confirmation) [3][21]
- Serum CK: Elevated in ~95% of LOPD (may be normal in some); up to 2000 IU/L in IOPD [3][7]
- AST, ALT, LDH: May be elevated from muscle origin (not hepatic) [7]
- Urinary glucotetrasaccharide (Hex4): Sensitive in IOPD; less reliable in LOPD; useful for monitoring treatment response [3]
- BNP: If concern for evolving cardiomyopathy [3]
- Anti-rhGAA antibody titers: Monitor in patients on ERT, especially CRIM-negative patients [2]
- Pseudodeficiency alleles must be considered when interpreting low GAA activity on DBS [20]
The following figure illustrates the diagnostic algorithm for follow-up of suspected Pompe disease identified by newborn screening:
12. Imaging
- Chest X-ray: Massive cardiomegaly in IOPD (classic finding); rarely abnormal in LOPD [7]
- Echocardiography: Hypertrophic cardiomyopathy ± LVOT obstruction in IOPD; assess for aortic dilatation in LOPD; monitor LV mass index on ERT [3]
- Muscle MRI: Demonstrates fatty infiltration and edema in paraspinal, gluteal, and thigh muscles; useful for monitoring disease burden and treatment response [1]
- Whole-body MRI: Recommended as clinically indicated to evaluate muscle disease burden [3]
- Brain MRA: At least every 5 years to evaluate for progressive dilation of cerebral vasculature (intracranial vasculopathy) [3]
- DEXA scan: Screen all patients regardless of age for osteoporosis; annual follow-up in LOPD [3][14]
13. Special Tests
- Pulmonary function tests (PFTs): FVC upright and supine (>10% drop supine = diaphragmatic weakness); MIP/MEP; at least annually [3][14]
- Polysomnography: Evaluate for sleep-disordered breathing, nocturnal hypoventilation [3]
- EMG/nerve conduction studies: Myopathic pattern; fibrillation potentials and myotonic discharges (especially in paraspinal muscles); useful in LOPD workup [7]
- Muscle biopsy: Glycogen-filled vacuoles, PAS-positive material, acid phosphatase-positive lysosomes; increasingly replaced by enzyme/genetic testing [4]
- Videofluoroscopic swallowing study: Baseline in all newly diagnosed cases to assess aspiration risk [7]
- 6-minute walk test (6MWT): Functional outcome measure for monitoring treatment response [9]
- CRIM status determination: Essential before initiating ERT in IOPD — determines need for immunomodulation [3]
14. ECG
- IOPD (classic findings):
- Short PR interval (~75% of infantile cases) — due to glycogen accumulation in conduction tissue acting as an insulator [7]
- Very tall QRS complexes (high voltage) — caution: if gain is turned down, this diagnostic clue may be missed [7]
- Pre-excitation patterns (WPW-like) [19]
- Repolarization abnormalities, bundle branch blocks, AV blocks [19]
- LOPD: ECG is typically normal or shows only nonspecific changes; cardiac involvement is infrequent [6-7]
- Monitoring: 24-hour Holter monitoring recommended at regular intervals due to arrhythmia risk, especially in IOPD on ERT (ventricular ectopy has been noted during reverse remodeling) [7]
- Dangerous patterns: Ventricular tachyarrhythmias in the setting of massive hypertrophy and subendocardial ischemia [7]
15. Assessment
- Two main phenotypes:
- IOPD: Near-complete GAA deficiency; presents within first months of life with hypotonia, cardiomyopathy, respiratory failure; fatal by age 1 year without treatment [2-3]
- LOPD (>80% of cases): Partial GAA deficiency; progressive limb-girdle and respiratory muscle weakness; onset from childhood to 7th decade; respiratory failure is the leading cause of death [2][4]
- Severity stratification: Determined by residual enzyme activity, CRIM status, specific GAA mutations, and disease duration rather than age [2][4]
- Atypical presentations: Isolated respiratory failure, unexplained hyperCKemia, isolated scapular winging, exercise-induced rhabdomyolysis [6][17]
- Complications: Respiratory failure requiring ventilation, wheelchair dependence, aspiration pneumonia, osteoporosis/fractures, scoliosis, arteriopathy/aortic aneurysm, hearing loss [3]
- Average diagnostic delay of 4.1 years in LOPD — a "must-not-miss" diagnosis [17]
16. Treatment Plan
Initial stabilization (ED/acute setting)
- Airway management with caution — avoid succinylcholine and volatile agents; prefer ketamine/etomidate if anesthesia needed [7][11]
- Non-invasive ventilation (BiPAP) for respiratory failure; avoid intubation if possible [3][11]
- Maintain euvolemia — avoid hypotension (worsens LVOT obstruction) and fluid overload (pulmonary edema risk) [7]
- Avoid digoxin, inotropes, and afterload reducers in early IOPD with LVOT obstruction [3][7]
Disease-specific therapy
- ERT initiation: As soon as diagnosis confirmed in IOPD; in LOPD, initiate when symptoms develop or show progression [3][24]
- Alglucosidase alfa 20 mg/kg IV q2 weeks (standard); IOPD often started at 40 mg/kg q2 weeks or weekly [2][4]
- Avalglucosidase alfa 20 mg/kg IV q2 weeks for LOPD — demonstrated superiority in respiratory outcomes vs. alglucosidase alfa in the COMET trial [9][25]
- Cipaglucosidase alfa + miglustat for LOPD adults ≥40 kg not improving on current ERT [2][10]
- Immunomodulation for CRIM-negative IOPD patients before first ERT infusion [3]
Supportive care
- Physical therapy: submaximal aerobic exercise (60–70% max effort, 3–5 days/week), stretching, balance training [14]
- High-protein diet (2 g/kg/day) as adjunct to ERT [12-13]
- Respiratory support: CPAP/BiPAP for nocturnal hypoventilation; inspiratory/expiratory muscle training [3]
- Nutritional support: feeding therapy, texture modification, gastrostomy if aspiration risk is high [7]
- Orthopedic management: scoliosis monitoring, surgical intervention if Cobb angle 30–40° [14]
- Vitamin D, calcium, bisphosphonates for bone health [14]
Emerging therapies
- Gene therapy (AAV9-mediated GAA gene delivery) has shown promising results in IOPD, with improvements in motor milestones and cardiac remodeling [26]
17. Disposition
- Admit:
- Acute respiratory failure or significant respiratory decompensation
- New-onset or worsening cardiomyopathy/arrhythmia (IOPD)
- Aspiration pneumonia
- Infusion-associated reactions with anaphylaxis or hemodynamic instability
- Need for anesthesia/surgical procedures (ICU-level monitoring recommended) [7]
- Newly diagnosed IOPD (urgent initiation of ERT and multidisciplinary evaluation)
- Observation: Mild infusion-associated reactions; respiratory infections in patients with borderline respiratory function
- Discharge: Stable known LOPD patients with minor complaints; ensure follow-up with metabolic/neuromuscular specialist
- Specialist consultation triggers: Genetics/metabolic medicine, neurology, pulmonology, cardiology (especially pediatric cardiology for IOPD), anesthesiology (for any procedural sedation), speech pathology, nutrition [10][14]
18. Follow Up / Return Precautions
Surveillance schedule (per GeneReviews/ACMG): [3]
- Each visit: Growth parameters, nutritional status, oral intake safety, respiratory symptoms, mobility assessment, CK, Hex4, electrolytes, LFTs, BUN/creatinine
- At least annually: PFTs, echocardiography (including aortic assessment in LOPD), ECG, audiology, DEXA (LOPD), BNP if cardiac concerns
- Every 5 years: MR cerebral angiography for cerebral vasculopathy
- As indicated: Polysomnography, videofluoroscopic swallow study, whole-body MRI, Holter monitoring
Return precautions
- Seek immediate care for: Increasing shortness of breath (especially when lying flat), new-onset morning headaches or daytime somnolence, difficulty swallowing or choking episodes, palpitations or syncope, rapid loss of motor function, signs of respiratory infection [2][5]
- Patient counseling: Disease is progressive but treatable; ERT slows but does not halt progression; adherence to biweekly infusions is critical; exercise and dietary modifications are beneficial adjuncts [12][14]
- Expected course: IOPD with early ERT — improved survival and cardiac remodeling, but long-term survivors may develop new phenotype with distal weakness. LOPD on ERT — initial stabilization/improvement over 2–3 years, followed by plateau or gradual decline in some patients [2][27]
- Genetic counseling: 25% recurrence risk per pregnancy; carrier testing and prenatal diagnosis available; test all at-risk siblings [3]
References
1. Skeletal muscle magnetic resonance imaging in Pompe disease. — Díaz-Manera J, Walter G, Straub V. Muscle & Nerve. 2021.
2. Clinical Insights in Enzyme Replacement Therapy for Metabolic Storage Disorders: Lessons From Pompe Disease. — van der Beek NAME, Theunissen MTM, van den Hout JMP, et al. The Lancet. Neurology. 2025.
3. Pompe Disease. — Sperry E, Leslie N, Berry L, et al GeneReviews® [Internet]. 2025.
4. Enzyme Replacement Therapy for Late-Onset Pompe Disease. — Dalmia S, Sharma R, Ramaswami U, et al. The Cochrane Database of Systematic Reviews. 2023.
5. Lysosomal Storage Diseases: Diagnostic Confirmation and Management of Presymptomatic Individuals. — Wang RY, Bodamer OA, Watson MS, Wilcox WR. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 2011.
6. Cardiac Phenotypes in Hereditary Muscle Disorders: JACC State-of-the-Art Review. — Arbustini E, Di Toro A, Giuliani L, et al. Journal of the American College of Cardiology. 2018.
7. Pompe Disease Diagnosis and Management Guideline. — Kishnani PS, Steiner RD, Bali D, et al. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 2006.
8. FDA Orange Book. — FDA Orange Book. 2026.
9. Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial. — Kishnani PS, Diaz-Manera J, Toscano A, et al. JAMA Neurology. 2023.
10. Cipaglucosidase Alfa and Miglustat for Treatment of Late-Onset Pompe Disease (LOPD): A Therapeutics Bulletin of the American College of Medical Genetics and Genomics (ACMG). — Baker EK, Derry A, Cohen JL, Chang IJ, ACMG Therapeutics Committee5∗documents@acmg.net. Genetics in Medicine Open. 2025.
11. Neuromuscular Disorders and the Role Of the Clinical Electrophysiologist. — Ismail H, Raynor E, Zimetbaum P. JACC. Clinical Electrophysiology. 2017.
12. Exercise Training Alone or in Combination With High-Protein Diet in Patients With Late Onset Pompe Disease: Results of a Cross Over Study. — Sechi A, Zuccarelli L, Grassi B, et al. Orphanet Journal of Rare Diseases. 2020.
13. Physical Training and High-Protein Diet Improved Muscle Strength, Parent-Reported Fatigue, and Physical Quality of Life in Children With Pompe Disease. — Scheffers LE, Somers OC, Dulfer K, et al. Journal of Inherited Metabolic Disease. 2023.
14. Consensus treatment recommendations for late‐onset Pompe disease. — Cupler EJ, Berger KI, Leshner RT, et al. Muscle & Nerve. 2012.
15. Pompe's Disease. — van der Ploeg AT, Reuser AJ. Lancet. 2008.
16. Enzyme Replacement Therapy for Infantile-Onset Pompe Disease. — Chen M, Zhang L, Quan S. The Cochrane Database of Systematic Reviews. 2017.
17. Pompe disease, the must‐not‐miss diagnosis: A report of 3 patients. — Dubrovsky A, Corderi J, Karasarides T, Taratuto AL. Muscle & Nerve. 2013.
18. Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association. — Lipshultz SE, Law YM, Asante-Korang A, et al. Circulation. 2019.
19. International Consensus on Differential Diagnosis and Management of Patients With Danon Disease: JACC State-of-the-Art Review. — Hong KN, Eshraghian EA, Arad M, et al. Journal of the American College of Cardiology. 2023.
20. Maximizing the Benefit of Life-Saving Treatments for Pompe Disease, Spinal Muscular Atrophy, and Duchenne Muscular Dystrophy Through Newborn Screening: Essential Steps. — Baker M, Griggs R, Byrne B, et al. JAMA Neurology. 2019.
21. The Initial Evaluation of Patients After Positive Newborn Screening: Recommended Algorithms Leading to a Confirmed Diagnosis of Pompe Disease. — Burton BK, Kronn DF, Hwu WL, Kishnani PS. Pediatrics. 2017.
22. Mass Spectrometry but Not Fluorimetry Distinguishes Affected and Pseudodeficiency Patients in Newborn Screening for Pompe Disease. — Liao HC, Chan MJ, Yang CF, et al. Clinical Chemistry. 2017.
23. Newborn Screening for Lysosomal Storage Diseases. — Roy W.A. Peake Lysosomal Storage Disorders. 2022.
24. Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum. — Kronn DF, Day-Salvatore D, Hwu WL, et al. Pediatrics. 2017.
25. Safety and Efficacy of Avalglucosidase Alfa Versus Alglucosidase Alfa in Patients With Late-Onset Pompe Disease (COMET): A Phase 3, Randomised, Multicentre Trial. — Diaz-Manera J, Kishnani PS, Kushlaf H, et al. The Lancet. Neurology. 2021.
26. AAV9-Mediated Gene Therapy for Infantile-Onset Pompe’s Disease. — Ma X, Zhuang L, Ma W, et al. The New England Journal of Medicine. 2025.
27. Safety and Efficacy of Cipaglucosidase Alfa Plus Miglustat Versus Alglucosidase Alfa Plus Placebo in Late-Onset Pompe Disease (PROPEL): An International, Randomised, Double-Blind, Parallel-Group, Phase 3 Trial. — Schoser B, Roberts M, Byrne BJ, et al. The Lancet. Neurology. 2021.